June 2, 2017: Investigator Spotlight Dr. Ryan Alan Wilcox Ryan Alan Wilcox, M.D., Ph.D., assistant professor of hematology, University of Michigan Comprehensive Cancer Center Member of the Big Ten Cancer Research Consortium Lymphoid Malignancies Clinical Trial Working Group Interests: T-cell non-Hodgkin’s lymphomas Medical School or Training Mayo Medical School, 2004 Residency Mayo Clinic, Internal Medicine, MN, 2007 Fellowship Hematology/Oncology, Mayo Clinic, 2011 Board Certification Internal Medicine Medical Oncology Hematology Read More
May 31, 2017: Dustin Deming, MD, is a gastrointestinal oncologist at the University of Wisconsin Carbone Cancer Center (UWCCC) and the William S. Middleton Veterans Hospital with subspecialties in the treatment of colon, rectal, and anal cancers. Deming’s commitment to the field is no coincidence; his first-hand exposure to clinical oncology opened his eyes to opportunities to apply his lab science strengths. “I had thought I wanted to be a pathologist and focus mostly on basic science research, because I had kind of been a lab rat for the beginning portion of my career. Once I actually got into the clinic, I realized how exciting it was to be involved in many aspects of colorectal research: things as... Read More
May 26, 2017: Lung cancer researchers at the Indiana University Melvin and Bren Simon Cancer Center have opened a clinical trial testing the effects of immunotherapy in combination with next-line chemotherapy in patients who experienced some benefit from immunotherapy before their disease worsened. The single-arm phase II study, known as BTCRC-LUN15-029, will enroll about 35 subjects with advanced non-small cell lung cancer who were treated with a PD-1 (programmed death-1) or PD-L1 (programmed death-ligand 1) inhibitor and experienced either stable disease or a partial or complete response before their disease worsened. The study is now open to accrual at the Indiana University Melvin... Read More
May 26, 2017: A Big Ten Cancer Research Consortium study is evaluating the safety and efficacy of durvalumab (MEDI4736) following multi-modality therapy in esophageal cancer. The phase II study, known as BTCRC-ESO14-012, is currently open for accrual at the Indiana University Melvin and Bren Simon Cancer Center, the University of Illinois Cancer Center, the Holden Comprehensive Cancer Center at the University of Iowa, Michigan State University Breslin Cancer Center, and the University of Michigan Comprehensive Cancer Center. Read More
May 22, 2017: Across the Consortium is your chance to catch the latest news in Big Ten oncology as it happens each month. We handpick the breaking stories that keep you informed and inspired. This month's edition highlights major breakthroughs in diagnostics, therapeutics, and discovery. Read More
May 15, 2017: Jatin Rana, MD Investigator Spotlight Jatin Rana, MD Educational Background: BS from University of Michigan, MS from Wayne State University, and MD from Wayne State University Research Interests: My primary interests both clinically and investigational is in gastrointestinal and breast malignancies. As a young investigator I'm excited to offer treatment opportunities through clinical trials for my patients. I am also involved in developing quality improvement projects to provide the best oncology care for our patients. Fun Facts: I enjoy cooking/grilling. I enjoy hands-on projects including fixing cars and working in the yard. I was born in England. Read More
May 7, 2017: The skin protects against heat, sunlight, injury, and infection. Skin also helps control body temperature and stores water and fat. Skin cancer is the most common type of cancer. It usually forms in skin that has been exposed to sunlight, but can occur anywhere on the body. Skin has several layers. According to the National Cancer Institute, skin cancer begins in the epidermis (outer layer), which is made up of squamous cells, basal cells, and melanocytes. You can learn more about skin cancer, including melanoma, from the National Cancer Institute. May is Skin Cancer Detection and Prevention Month. This month, the members of the Big Ten Cancer Research... Read More
Apr. 21, 2017: Innovative therapies with hard-hitting impact; that must have been the game plan developed in the last huddle of the Big Ten Cancer Centers! This month's Across the Consortium is your instant replay of the amazing achievements making headlines across the country, from dynamic new treatments to prototype diagnostics for early detection. Be inspired as you catch all the action. Read More
April 19, 2017: The Big Ten Cancer Research Consortium will host meetings for the Big Ten CRC Foundation, Cancer Center Directors, Steering Committee, and Clinical Trial Working Groups during ASCO 2017. Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube